Assess whether to resubmit, meet, or pause the program (ca4ed0)

SITUATION After a site-change that invalidates stability claims, 505(b)(2) literature-to-product bridge table is what labeling negotiator can touch in a company with a CMC site change mid-review. Pharma & Life Sciences will live with To resubmit, meet, versus Pause the program on this Pharmacovigilance file.

DECISION Labeling negotiator in a company with a CMC site change mid-review must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; 505(b)(2) literature-to-product bridge table already has the discriminator after a site-change that invalidates stability claims. 2. Keep Pause the program in force until 505(b)(2) literature-to-product bridge table is completed after a site-change that invalidates stability claims for labeling negotiator. 3. Treat 505(b)(2) literature-to-product bridge table as To resubmit, meet, because both readings appear after a site-change that invalidates stability claims. 4. Refuse a Pharma & Life Sciences close: labeling negotiator does not have the decision to resubmit, meet, or turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim labeling negotiator would keep. 2. Map FDA-response timing and owner in a company with a CMC site change mid-review. 3. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims. 4. For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a site-change that invalidates stability claims and write the one fact that would move to resubmit, meet, or for labeling negotiator.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for labeling negotiator in a company with a CMC site change mid-review.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for labeling negotiator - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform